PMID- 15085463
OWN - NLM
STAT- MEDLINE
DCOM- 20050331
LR  - 20060307
IS  - 0094-6176 (Print)
IS  - 0094-6176 (Linking)
VI  - 30 Suppl 1
DP  - 2004 Feb
TI  - Low-molecular-weight heparin in thrombosis and cancer.
PG  - 25-30
AB  - Venous thromboembolism (VTE) is a recognized complication of malignant disease 
      and multiple risk factors contribute to the hypercoagulability that commonly 
      accompanies malignancy. Thromboprophylaxis with antithrombotic drugs such as the 
      low-molecular-weight heparins (LMWHs) can be used to control the hypercoagulable 
      state and to reduce the incidence of VTE in patients with cancer. Clinical and 
      biochemical data suggest that LMWHs may also inhibit tumor growth, leading to a 
      survival benefit in these patients. Many cancer patients reportedly have a 
      hypercoaguable state, with recurrent thrombosis due to the impact of cancer cells 
      and chemotherapy or radiotherapy on the coagulation cascade. Studies have 
      demonstrated that unfractionated heparin (UFH) or its low-molecular-weight 
      fractions interfere with various processes involved in tumor growth and 
      metastasis. Clinical trials in cancer patients with thromboembolic disorders have 
      suggested a clinically relevant effect of LMWHs (as compared with UFH) on the 
      survival of cancer patients with deep vein thrombosis. Similarly, the impact of 
      warfarin on the survival of cancer patients with thromboembolic disorders was 
      demonstrated in certain tumor types. Studies from our laboratory demonstrated a 
      significant role for LMWH, warfarin, anti-VIIa, and LMWH releasable tissue factor 
      pathway inhibitor on the regulation of angiogenesis, tumor growth, and tumor 
      metastasis. However, a direct anticancer effect for heparin in cancer patients 
      without thrombosis still remains to be clinically documented.
FAU - Mousa, Shaker A
AU  - Mousa SA
AD  - Albany College of Pharmacy and Pharmaceutical Research Institute (PRI) at Albany, 
      Albany, New York 10001, USA. mousas@acp.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Hemostasis
MH  - Heparin, Low-Molecular-Weight/*therapeutic use
MH  - Humans
MH  - Neoplasms/complications/*drug therapy
MH  - Neovascularization, Pathologic/drug therapy/etiology
MH  - Thrombosis/*drug therapy/prevention & control
RF  - 40
EDAT- 2004/04/16 05:00
MHDA- 2005/04/01 09:00
CRDT- 2004/04/16 05:00
PHST- 2004/04/16 05:00 [pubmed]
PHST- 2005/04/01 09:00 [medline]
PHST- 2004/04/16 05:00 [entrez]
AID - 10.1055/s-2004-823000 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2004 Feb;30 Suppl 1:25-30. doi: 10.1055/s-2004-823000.